The US Food and Drug Administration won’t penalize manufacturers of non-invasive fetal and maternal monitoring devices if they make changes to their products so they can be used in a home setting during the COVID-19 pandemic.
That’s the message from an immediately-in-effect guidance document released by the agency on 23 April, “Enforcement Policy for Non-Invasive...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?